Pharmaceutical Negotiations Decoded: The Complete Guide for IP, R&D, and Institutional Investors
A deep-dive analysis for pharma/biotech IP teams, R&D leads, and institutional investors. Introduction: How a Single Negotiation Rewires a Drug’s […]
Insights
Generic Drug Development: The Complete IP, Regulatory, and Market Strategy Playbook
Why the Cheapest Generic Manufacturer Usually Loses The dominant assumption inside generic pharma for the past three decades has been
Generic Drug Development: The Complete IP, Regulatory, and Market Strategy Playbook Read Post »
Biosimilar Market Dynamics Across Patient Populations: The Definitive Strategic Analysis for IP Teams, R&D Leads, and Institutional Investors
1. Why This Analysis Exists: The $234 Billion Question Nobody Is Answering Precisely Between 2025 and 2034, 118 biologic medicines
Drug Patent Strategy: The Definitive Guide for Pharmaceutical IP Teams, R&D Leads, and Institutional Investors
I. Executive Summary and Scope The $1.6 trillion global pharmaceutical industry runs on a single underlying premise: time-limited exclusivity justifies
Generic Drug Patient Education: The Complete Playbook for Pharma Teams, Payers, and Health Systems
Executive Summary Generic drugs now account for roughly 90% of all U.S. prescriptions filled, yet constitute less than 13% of
Japan Generic Drug Development: The Complete Strategic and Regulatory Playbook for IP Teams, R&D Leads, and Institutional Investors
A deep-dive for pharma/biotech IP strategists, pipeline analysts, and buy-side investors. Part I: The Japanese Pharmaceutical Market Sizing Up the
Generic Drugs Save America $445 Billion a Year. Here’s Why the Model Is Cracking.
The pharmacy counter is one of the most consequential decision points in American healthcare. A prescription that a physician deemed
Generic Drugs Save America $445 Billion a Year. Here’s Why the Model Is Cracking. Read Post »
Drug Patent Portfolio Strategy: The Complete Playbook for Market Exclusivity, IP Valuation, and Competitive Defense
Who this is for: Pharma and biotech IP teams, portfolio managers, R&D leads, M&A counsel, and institutional investors with exposure
Drug Patent Prosecution: The Complete Strategic Playbook for Pharma IP Teams
Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different
Drug Patent Prosecution: The Complete Strategic Playbook for Pharma IP Teams Read Post »
